New initiative from late-stage research and patient-support services organization aims to accelerate COVID-19 vaccine development.
UBC, a late-stage research and patient-support services organization, is announcing an offering to harness the power of real-world data (RWD) for rapid generation of insights into the safety and effectiveness of COVID-19 vaccines.
As vaccine manufacturers prepare for post authorization surveillance initiatives to generate outcome evidence in real-world settings, the ability to rapidly automate analysis of large-scale representative databases is essential.
The real-world data analyses will be made possible through a collaboration with companies such as global healthcare technology company Cerner Corporation and its Cerner Real-World Data, a national, de-identified data set including approximately 92 million patients from 90 health systems.
The integration of UBC’s analytical tools and epidemiologic expertise with real-world data enables researchers to customize and automate insights from the front lines of vaccine and healthcare delivery.
For more information, click here.